Format

Send to

Choose Destination
Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0732-9. [Epub ahead of print]

Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Author information

1
Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.
2
Lymphoma Working Party, EBMT, Paris, France.
3
Pathology Department, Hospital Universitari de Bellvitge, Barcelona, Spain.
4
Hematology Department, Hopital St. Louis, Paris, France.
5
Universitaetklinikum, Dresden, Germany.
6
Hope Directorate, St. James's Hospital, Dublin, Ireland.
7
University Hospital Center Rebro, Zagreb, Croatia.
8
University of Münster, Muenster, Germany.
9
Department of Internal Medicine, University of Saarland, Homburg, Germany.
10
Department of Hematology and Oncology, University Hospital Bristol, Bristol, UK.
11
St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
12
Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain. asureda@iconcologia.net.
13
Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.

Abstract

Information regarding the curative role of allogeneic stem cell transplantation (allo-HCT) in systemic anaplastic large cell lymphoma (sALCL) is scarce. We analyzed the results of allo-HCT in patients with relapsed/refractory sALCL with special emphasis on the role of brentuximab vedotin (BV) as a bridge to allo-HCT. Forty-four patients (24 females, median age 38 years) with sALCL were included. Twenty-three patients (52%) received BV before allo-HCT; BV-treated patients were more heavily pretreated (≥3 lines of therapy in 74% vs. 38%, p = 0.04). Twenty-three patients (52%) were in complete remission (CR) at allo-HCT. Three-year nonrelapse mortality and incidence of relapse (IR) after allo-HCT were 7% and 40%, respectively. With a median follow-up of 39 (12-69) months for survivors, 3-year progression-free survival (PFS) and overall survival were 53% and 74%, respectively. Univariate analysis showed that heavily pretreated patients and those not in CR had a higher IR and a lower PFS. The use of BV before transplant did not impact on any of the outcomes. Allo-HCT is a curative therapeutic strategy in a significant proportion of patients with relapsed/refractory sALCL; BV does not seem to modify transplant-related outcomes but might be able to render more patients candidates for this curative treatment.

PMID:
31695173
DOI:
10.1038/s41409-019-0732-9

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center